Checkout our new paper: Magnetic Resonance Imaging of Atherosclerotic Plaque at Clinically Relevant Field Strengths (1T) by Targeting the Integrin α4β1.PUBMED
https://www.ncbi.nlm.nih.gov/pubmed/29487319
Texas Heart Institute has developed a new technology that allows a cargo in a liposome to be selectively delivered to tissues expressing α4β1. This is important because plaques express this integrin and we are working on derivatives of this concept for other cargos and other integrins. Imagine therapeutics loaded in the liposome and brought at higher local concentration selectively to the plaques.